| Document Date: 2014-11-03 11:26:23
Open Document File Size: 21,43 KBShare Result on Facebook
City Osaka / / Company Shionogi & Co. Ltd. / Corporate Communications Department Shionogi & Co. Ltd. / / Country Japan / / Currency JPY / / Event FDA Phase / / / IndustryTerm treatment of infectious diseases / manufacturing capability / foreign healthcare reforms / / MedicalCondition influenza infections / pediatric influenza infections / influenza infection / seasonal influenza virus infection / infectious diseases / diarrhea / infection / severe and life-threatening influenza / influenza A / influenza / / Organization Ministry of Health / / Person Isao Teshirogi / / / Position President and Representative / Director / / Product Shionogi Receives / RAPIACTA® / /
SocialTag |
Shionogi & Co., Ltd. Shionogi Receives an Approval for an Additional Indication for Pediatric Use of RAPIACTA®, a Novel Anti-viral Drug for Influenza